While Europe’s biotech sector continues to face headwinds, med tech appears to be weathering the storm more effectively. Uncertainty in the U.S., heightened competition from China and a persistent ...
About a month after rolling out positive phase I/II data with its candidate for metastatic, castrate-resistant prostate ...
Over a span of five-and-a-half months this year, 3.5% of the more than 11,000 clinical trials funded by the U.S. NIH had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback